Home / Medical Marijuana  / 2015 Canadian Medical Marijuana Outlook: Foggy with Sunny Patches

2015 Canadian Medical Marijuana Outlook: Foggy with Sunny Patches

by James West

The Canadian Medical Marijuana experience for investors has for the most part been a tremendous letdown thus far. When Tweed Marijuana Inc. (TSX.V:TWD) lost 10 percent on its first day open of $3.32, and as of Friday last week accumulated a total YTD loss of 41 percent, the writing was on the wall.

Of course, that does not apply to insiders and early stage investors. Tweed founders paid as little as $0.15 a share, and their instant wealth came at the direct expense of retail investors.

But that is the game, and anybody who cries about it has no business investing in it.

Since Tweed’s underwhelming debut, there have been millions of dollars vaped by both licensed producers who are publicly traded, publicly traded mining companies who say they are on the cusp of a sex change, and even private co’s who are locked in liquidity limbo as their applications for production licenses flutter uselessly in the wind like war-ravaged flags. ‘Burn rate’ has taken on a whole new meaning in this context.

From the abysmal and bizarre rantings of CEN Biotech’s embarrassing and ludicrous claims that its going to produce “600,000 kilograms” of dried marijuana per year, to the quiet sophistication of Bedrocan Canada’s automated no-touch production systems for genetically identical strains of pharmaceutical grade marijuana, the range of experiences for investors mirrors the range of credibility in the industry.

A year into the publicly traded marijuana company experience, profit and capital gains remain elusive. So what’s the prognosis? Where is there a credible forecast on who’s going to win and who’s going to lose?

The Canadian Securities Regulators, in classic ‘slam-shut-the-barn-doors-after-the-horses-escaped’ form, issued a second warning against the medical marijuana industry as a whole.

As with any industry, there are always an evolving set of threats and opportunities that are exacerbated or ameliorated according to individual strengths and weaknesses.

Here then is an overview of those threats and opportunities, followed by a summary take on each of the publicly traded medical marijuana companies.

Industry-Wide Threats Specific to Canadian MMPR Companies

There are two significant threats to the entire MMPR-regulated roster of companies that could send the entire industry into a terminal downward spiral.

The Allard Case
Just before the official MMPR rules took effect on April 1st, 2014, a group of medical marijuana users who were licensed under the forerunner to MMPR, Medical Marijuana Access Regulations, challenged in the Supreme Court of British Columbia the constitutionality of being forced to source their weed from MMPR registered growers.

They were successful, and obtained Injunctive Relief from Judge Michael Manson who found that, among other conclusions,

“The Applicants who held, as of September 30, 2013, or were issued thereafter a valid Personal-use Production License pursuant to section 24 of the Marihuana Medical Access Regulations, or a Designated-person Production Licence pursuant to section 34 of the Marihuana Medical Access Regulations, are exempt from the repeal of the Marihuana Medical Access Regulations and any other operation of the Marihuana for Medical Purposes Regulations which is inconsistent with the operation of the Marihuana Medical Access Regulations, to the extent that the Designated-person Production License or Personal-use Production License held by the Applicant shall remain valid until such time as a decision in this case is rendered at trial and subject to the terms of paragraph 4 of this Order”

So they are allowed to continue to grow their own and source their own until the outcome of the supreme court appeal by Health Canada, now in its fourth week in Vancouver, British Columbia.

The implication, if the Supreme Court decides to permanently enshrine an individual’s right to grow their own marijuana in law, is that all Canadian medical users of marijuana might then have the right to produce their own pot over sourcing it from MMPR growers, thus undermining the entire investment thesis of the industry.

Growers who I’ve spoken with disagree, and uniformly opine that regardless of the outcome of the Allard challenge, MMPR will apply to all subsequent prescription holders of medical marijuana. That belief, however, is inconsistent with history, and smacks more of a belief in what they need to believe.

So that’s one major potential wrinkle in the blanket.

Vancouver Cops Not Enforcing Laws
Meanwhile, in Vancouver, city police have elected to ignore the law against marijuana sale and possession, which has given rise to at least 60 new ‘dispensaries’ that provide weed for as little as $4 a gram. While there is supposedly a requirement for a doctor’s prescription, those without can log onto Skype and receive one in under two minutes simply by claiming stress as a medical condition. Essentially, this is a wide open market for recreational marijuana.

This is tantamount to undermining the viability of licensed producers and of the entire MMPR regime. If these unregulated and thus lower cost vendors are allowed to proliferate, it will be very difficult for MMPR producers to garner market share.

In the United States, Washington State growers are already going out of business en masse thanks to a glut of supply, and the same is nervously anticipated in Colorado. The problem of course being that, at the end of the day, marijuana is about as tough to grow as canola, and will suffer commodity pricing as a result. Thus only the biggest, cheapest growers will survive.

Performance Lacking

Here’s the visual summary of the publicly traded MMPR producer’s performance to date. The order reflects the order in which the companies went public.

Tweed Marijuana Inc.

(TSX: TWD.V)

Last Trade: 2.02 Day’s Range 2.002.10
Trade Time: Mar 17 52wk Range: 0.01 – 4.75
Change: down-0.07 (-3.35%) Volume: 122,122
Prev Close: 2.09 Avg Vol (3m): 119,798
Open: 2.10 Market Cap: 82.09M
Bid: 2.01 x N/A P/E (ttm): N/A
Ask: 2.08 x N/A EPS (ttm): -0.30
1Y Target Est: N/A Div & Yield: N/A (N/A)
Chart showing the development of {0:name}

Midas-Letter-financial-radio-podcast-thumb[four_fifth_last padding=”0 0 0 20px”]Listen to an interview with Tweed Marijuana CEO Bruce Linton:

[/four_fifth_last]


Bedrocan Cannabis Corp

(TSX: BED.V)

Last Trade: 0.77 Day’s Range 0.750.77
Trade Time: Mar 17 52wk Range: 0.50 – 1.45
Change: up+0.03 (+4.05%) Volume: 189,687
Prev Close: 0.74 Avg Vol (3m): 211,348
Open: 0.75 Market Cap: 53.49M
Bid: 0.76 x N/A P/E (ttm): N/A
Ask: 0.78 x N/A EPS (ttm): -0.02
1Y Target Est: N/A Div & Yield: N/A (N/A)
Chart showing the development of {0:name}

Midas-Letter-financial-radio-podcast-thumb[four_fifth_last padding=”0 0 0 20px”]Listen to the interview with Bedrocan CEO Marc Wayne:

[/four_fifth_last]


OrganiGram Holdings Inc

(TSX: OGI.V)

Last Trade: 0.43 Day’s Range 0.430.46
Trade Time: Mar 17 52wk Range: 0.07 – 2.40
Change: down-0.03 (-6.52%) Volume: 136,119
Prev Close: 0.46 Avg Vol (3m): 97,601
Open: 0.46 Market Cap: 21.94M
Bid: 0.43 x N/A P/E (ttm): N/A
Ask: 0.44 x N/A EPS (ttm): -0.41
1Y Target Est: N/A Div & Yield: N/A (N/A)
Chart showing the development of {0:name}

Midas-Letter-financial-radio-podcast-thumb[four_fifth_last padding=”0 0 0 20px”]Listen to an interview with OrganiGram CEO Denis Arsenault:

[/four_fifth_last]


T-Bird Pharma Inc.

(TSX: TPI.V)

Last Trade: 0.495 Day’s Range 0.4950.55
Trade Time: Mar 17 52wk Range: 0.35 – 0.95
Change: down-0.035 (-6.60%) Volume: 58,306
Prev Close: 0.53 Avg Vol (3m): 74,405
Open: 0.53 Market Cap: 22.805M
Bid: 0.495 x N/A P/E (ttm): N/A
Ask: 0.55 x N/A EPS (ttm): -0.04
1Y Target Est: N/A Div & Yield: N/A (N/A)
Chart showing the development of {0:name}

Midas-Letter-financial-radio-podcast-thumb[four_fifth_last padding=”0 0 0 20px”]Listen to an interview with T-Bird Pharma CEO Robert Gagnon:

[/four_fifth_last]


Mettrum Health Corp.

(CDNX: MT.V)

Last Trade: 2.00 Day’s Range 2.002.00
Trade Time: Mar 17 52wk Range: 1.50 – 2.49
Change: 0.00 (0.00%) Volume: 2,590
Prev Close: 2.00 Avg Vol (3m): 13,838
Open: 2.00 Market Cap: 67.43M
Bid: 1.95 x N/A P/E (ttm): N/A
Ask: 2 x N/A EPS (ttm): -0.27
1Y Target Est: N/A Div & Yield: N/A (N/A)
Chart showing the development of {0:name}

Midas-Letter-financial-radio-podcast-thumb[four_fifth_last padding=”0 0 0 20px”]No Interview with Mettrum CEO Michael Haines despite multiple invitations:

[/four_fifth_last]


PharmaCan Capital Corp

(TSX: MJN.V)

Last Trade: 0.60 Day’s Range 0.590.60
Trade Time: Mar 17 52wk Range: 0.48 – 1.00
Change: down-0.02 (-3.23%) Volume: 8,000
Prev Close: 0.62 Avg Vol (3m): 48,067
Open: 0.60 Market Cap: 9.22M
Bid: 0.5 x N/A P/E (ttm): N/A
Ask: 0.62 x N/A EPS (ttm): -0.17
1Y Target Est: N/A Div & Yield: N/A (N/A)
Chart showing the development of {0:name}

Midas-Letter-financial-radio-podcast-thumb[four_fifth_last padding=”0 0 0 20px”]Listen to an interview with PharmaCan CEO Paul Rosen:

[/four_fifth_last]


Aphria Inc

(TSX: APH.V)

Last Trade: 0.87 Day’s Range 0.840.87
Trade Time: Mar 17 52wk Range: 0.40 – 1.20
Change: up+0.05 (+6.10%) Volume: 30,187
Prev Close: 0.82 Avg Vol (3m): 85,669
Open: 0.84 Market Cap: 33.65M
Bid: 0.78 x N/A P/E (ttm): N/A
Ask: 0.87 x N/A EPS (ttm): -0.12
1Y Target Est: N/A Div & Yield: N/A (N/A)
Chart showing the development of {0:name}

Midas-Letter-financial-radio-podcast-thumb[four_fifth_last padding=”0 0 0 20px”]No Interview with Aphria CEO Vic Neufeld available despite repeated invitations.

[/four_fifth_last]

Buy, Sell or Hold?

A lot of investors have rushed into the medical marijuana sector and lost their money. There is a new wave of publicly traded marijuana companies on the horizon, though these typically are not pure producers. MidasLetter ranks and quantifies all the producers publicly listed in Canada for subscribers.

Learn more at http://10.0.1.189:8888/midasletter_old/subscribe.

12 COMMENTS
  • Reverend Ryan March 18, 2015

    Considering the hostile tactics used under the Harper Government’s regime… this is ALL to be expected. The bait & switch happened at the Federal level as just another way to delay, deny and destroy the cannabis “industry”.

  • Voiceof thecitizens March 19, 2015

    These companies will be poised to supply the demand when cannabis prohibition ends.

    • Chris R March 19, 2015

      when cannabis prohibition ends then the price will drastically drop, People need to understand the plant will damn near grow its self, so we really do not need big companies to grow it, only people who for some reason do not want to grow or people who cant will be buying Cannabis.

      • Voiceof thecitizens March 24, 2015

        Top quality cannabis tested for impurities is not going to be grown at home. Kind of like, well I can brew me a little wine/beer or grab a bottle @ the store and kick back and relax. Sure there will be a few who have a green thumb and have the time to tend to and wait 6 months for their vice.

  • James Mitton March 19, 2015

    They need to Work more with the Doctors to Accept it and Prescribe it. I have More Sheet Metal in my Hip than a Foreign Car is Made off My Back is wrote off and when I asked the Doc about a Script She wouldn’t Even Consider it even thought I Told her that Cannabis Helps. She Prescribed some Synthetic Crap made in a Laboratory.

  • Al Boisvert March 19, 2015

    The Licensed Producers problems is not home growers there will be plenty of people who don’t want to or can not grow for one reason or another their problem is with Doctors being told by government that Cannabis is not medicine and the Provincial College and physicians and Surgeons.

  • whariwharangi March 19, 2015

    I’m having vibration in my home that I believe but cannot prove is being caused by machinery at an mmar grow op. The city is not willing to investigate my nuisance complaints probably because they are not competent to do so. My only option now is to go to court for an injunction. I cant afford to do that so all I can do is hope for the courts to uphold mmpr. Marijuana grow ops do not belong in residential areas.

    • Reverend Ryan March 24, 2015

      Picking up bad vibrations? …probably a fan running. Leave a note: ask ’em to fix the hum. With my neighbours it’s the broken screen door slamming in the wind.

      • whariwharangi March 24, 2015

        I’ve been there. All I got was a threat of charges for tresspassing. He stated there would be no cooperation. A slamming screen door is not a valid comparison to being kept awake by vibration. Wood frame houses are not intended to be used as industrial scale green houses.

  • miller06 March 21, 2015

    Afordable prices with over night discreet delivery. You can halla my line on (424)239-6907 or email me at buraskasia70@gmail.com for more details.
    I also got some pain killers and body building supplements. as below

    Ecstasy pills 20 mg
    cannabis 1g
    Oxy 30mg
    Roxi 30mg
    Hydrocodone 30mg
    ² 2mg
    Diazepam 10mg

    *Green Crack::::::::::::: Grade: AA
    *sour Diesel ::::::::Grade: A+ Top Shelf
    *Grand Daddy Purple ::::Grade: A
    *Sensi Star x ak47 :::::::Grade: AAA
    *Afghan Kush :::::::::::::Grade: A
    *Northe Lights #5 ::::::Grade: A+
    *Lemon drop:::::::::::::::Grade: A+
    *Purple Kush:::::::::::Grade:A+ Top Shelf
    *OG Kush ::::::::::Grade:A++ Top Shelf
    *purple-urkle::::::::::::::Grade: A-

    CONTACT: (424)239-6907 or email me at buraskasia70@gmail.com
    This pure indica medicinal strain comes from California. In that
    state’s medical community she is considered an “elite clone”, meaning
    that she is only available as a cutting. Not to worry if you are a
    medical merijuana patient in California – this strain can be found at
    various despensaries throughout the state. Purple Kush is especially
    popular at the SR-71 dispensary in “Oaksterdam”, the section of downtown
    Oakland that tolerates medical marijuana providers. Patients there
    praise this Purple Kush’s deep body stone as a treatment for pain and
    depression.

    This lady forms a short squat bush with very dense
    intermodes and huge fan leaves, staying in the 2-3 foot height range
    indoors. With topping or pinching she will be at least as wide as she is
    tall. Purple Kush’s foliage exhibits a classic indica growth pattern: a
    sturdy bush with dark green hues and hints of purple toward ripeness.

    Purple Kush is versatile, performing well for both indoor and outdoor
    growers. She does very well in a screen of green (SCROG) setup. Purple
    Kush buds form tight chunky nuggets with hints of purple in the tips of
    the calyxes, as well as the soft pine bouquet and a sweet, grapey taste
    on an earthy foundation. her very frosty veneer of glands will please
    both the connoisseur of indica potency and the hashish fan. The Purple
    Kush high is strong, deep stone delivers when it comes to treating
    chronic pains and inflamations, among other conditions.

    Grade: A+

    Type: Hindu Kush x Purple Afghani

    Looks:Light green nugs with purple coming out of the bud and leaves. Covered in crystals on top of crystals.

    Smell:Nice cold kushy smell very nice on the nostrils.

    Taste: Beautiful smooth cold expanding smoke in the mouth and in the lungs. Very good after taste

    Effects: Makes me tired and gets me couchlocked pretty quick

    ..,.,..,.,,

  • Doug Pederson May 2, 2015

    To the victor go the spoils
    This should apply to the Marijuana revolution as well.
    We have them down and by the throat. Let’s finish ’em off NOW.

    No licenses should go to people that weren’t involved in this victory.

    Only those who lost jobs or were incarcerated etc should get our support $$$ Period. We are a cohesive group and if we boycott those pretenders shops, they will soon be out of business.

    I read about one investor that owned over 60 licenses. Boo and boycott.

    Those $30,000 licenses will be worthless real fast.

POST A COMMENT

Sign up for our free newsletter

and get more of MidasLetter delivered to your inbox.

Receive With your NEW subscription

Free and immediate access to these three recently published special reports